Compare QTWO & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QTWO | TMDX |
|---|---|---|
| Founded | 2004 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.6B |
| IPO Year | 2014 | 2019 |
| Metric | QTWO | TMDX |
|---|---|---|
| Price | $50.50 | $147.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 9 |
| Target Price | $86.25 | ★ $152.33 |
| AVG Volume (30 Days) | ★ 1.3M | 696.8K |
| Earning Date | 05-13-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 225.00 | ★ 382.18 |
| EPS | 0.80 | ★ 4.87 |
| Revenue | $193,978,000.00 | ★ $605,494,000.00 |
| Revenue This Year | $12.48 | $21.96 |
| Revenue Next Year | $10.16 | $17.62 |
| P/E Ratio | $60.00 | ★ $29.64 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $46.16 | $62.07 |
| 52 Week High | $95.10 | $156.00 |
| Indicator | QTWO | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 35.68 | 62.53 |
| Support Level | N/A | $122.59 |
| Resistance Level | $75.62 | $153.93 |
| Average True Range (ATR) | 2.58 | 7.81 |
| MACD | 0.08 | 1.22 |
| Stochastic Oscillator | 32.82 | 98.62 |
Q2 Holdings Inc. is a provider of cloud-based virtual banking solutions for regional financial institutions to deliver mobile banking services to retail and commercial end-users who wish to bank anywhere and anytime. Its solutions operate on an integrated tablet-first platform which provides financial institutions a comprehensive view of account holder activity and meets the regulatory and security requirements applicable to the industry. The firm generates revenue from subscription-based arrangements for software offerings. A large majority of the firm's revenue is generated in the United States.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.